Friday's Small-Cap Winners & Losers

Intelli-Check (IDN Quote) rose after announcing it will perform identification-verification-related services for the Department of Homeland Security's EAGLE Program (Enterprise Acquisition Gateway for Leading Edge Solutions) using its own ID-check technology. Terms weren't disclosed. The Woodbury, N.Y., company separately announced it had appointed Peter Mundy as its new chief financial officer. Shares were gaining 29 cents, or 4.3%, to $7.10.

Hana Biosciences (HNAB Quote) took a nosedive on word it will stop development on the current formulation of its Zensana nasal spray drug, proposed to treat cancer-treatment side effects, and will accordingly withdraw Zensana's new drug application to the Food and Drug Administration.

Hana had warned this might happen last month after discovering precipitate (solid material) in the compound. The California-based biotech, along with NovaDel Pharma (NVD Quote), which is licensing the oral-spray technology used for the treatment, have already jointly developed an alternate formulation "currently under active investigation and scale-up." Hana shares were losing $1.34, or 36%, to $2.38. NovaDel stock was off 12 cents, or 8.6%, to $1.28.

Ceco Environmental (CECE Quote) plummeted on disappointing fourth-quarter results. The Cincinnati-based maker of air-pollution-control products swung to a 9-cent per-share profit, but two analysts polled by Thomson Financial were seeking 20 cents a share. Ceco's gross margin also dropped to 19.8% from last year's 26.2%, which the company blames on a change in its product mix due to rising turnkey sales. Shares were sliding $3.17, or 17.9%, to $14.55.